Literature DB >> 8044724

Cardiac screening of children with Down's syndrome.

H C Rosenberg1, J H Jung, H C Soltan, M D Li, G Sheridan.   

Abstract

OBJECTIVE: To establish the role of clinical and laboratory investigation of the cardiovascular system in children with Down's syndrome.
DESIGN: Prospective evaluation; examiners blinded to results of laboratory studies.
SETTING: Tertiary pediatric referral centre. PATIENTS: Fifty consecutive children with Down's syndrome presenting to a regional genetic centre. Children less than six weeks of age or with known heart disease were excluded. MEASURES: Following independent examinations by a geneticist and a pediatric cardiologist, an electrocardiogram (ECG) and two-dimensional and Doppler echocardiograms were carried out.
RESULTS: Assessment by the geneticist yielded two false positives and five false negatives (sensitivity 67%, specificity 88%). Addition of an ECG to clinical evaluation increased the sensitivity to 80% and specificity to 90%, a rate comparable with clinical assessment by a cardiologist. No lesion requiring surgical correction was missed by this combination.
CONCLUSIONS: Where expertise in pediatric echocardiography is not readily available, careful clinical assessment coupled with the interpretation of an ECG is adequate and appropriate screening of the child with Down's syndrome.

Entities:  

Mesh:

Year:  1994        PMID: 8044724

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  2 in total

1.  Screening for Congenital Heart Disease in Infants with Down Syndrome: Is Universal Echocardiography Necessary?

Authors:  Soujanya Bogarapu; Nelangi M Pinto; Susan P Etheridge; Xiaoming Sheng; Kirk N Liesemer; Paul C Young; Elizabeth V Saarel
Journal:  Pediatr Cardiol       Date:  2016-06-09       Impact factor: 1.655

2.  Prediction of ductus arteriosus closure by neonatal screening echocardiography.

Authors:  Sheng-Ling Jan; Betau Hwang; Yun-Ching Fu; Ching-Shiang Chi
Journal:  Int J Cardiovasc Imaging       Date:  2004-08       Impact factor: 2.357

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.